Immugenyx, LLC

#Hemogenyx Pharmaceuticals plc (LSE: HEMO), the #biopharmaceutical group announces that it will be presenting at the New York #Oncology #Investor #Conference being held on November 12 and 13 in New York, New York. https://www.londonstockexchange.com//ma/HEMO/14295995.html

#Immugenyx a wholly-owned subsidiary of #Hemogenyx signs a research agreement to develop humanized mice as a tool for drug development and testing. https://www.londonstockexchange.com//ma/HEMO/14276270.html

Our first poster at the New York Stem Cell Foundation (#NYSCF) conference! #Hemogenyx crew.

#Hemogenyx is supporting the Blood Health 2019 campaign from #Health Awareness. Learn more about the latest method of non-toxic bone marrow transplant condition...ing from the CEO of #Hemogenyx among other thought leaders from the American Society of Hematology and International Society of Hematology https://www.healthawareness.co.uk//new-approach-could-rem/ #BloodHealth See more

#Immugenyx has developed a new humanized mouse model. https://www.drugtargetreview.com//new-humanised-mouse-mod/

#HemoGenyx #ImmuGenyx Northland Capital Partners: Initiation of research: Disrupting current blood disease therapy. Northland Capital Partners View on the City - #HemoGenyx http://tinyurl.com/y8szuf2s

Orgenesis - our new partner! https://www.youtube.com/watch?v=Rzee2GIdiWc

Orgenesis teams up with @HemoGenyx to develop its AHC platform in ‘exciting’ deal https://www.youtube.com/watch?v=8WbgQOEJqwI&feature=youtu.be

Orgenesis Announces Collaboration with Hemogenyx to Develop Blood Stem Cell Replacement Product https://finance.yahoo.com//orgenesis-announces-collaborati Hemogenyx

@HemoGenyx Orgenesis (ORGS) Announces Pact with Hemogenyx Pharmaceuticals Plc (HEMO:LN) Subsidiary, Immugenyx, to Develop & Commercialize Advanced Hematopoietic Chimeras https://bit.ly/2q1ZHIn

https://www.proactiveinvestors.co.uk//hemogenyx-to-receive